间充质干细胞在肝脏再生中的机制：见解与未来方向。
Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions.
作者信息
Jin Yu-Xin, Hu Hang-Qi, Zhang Jia-Cheng, Xin Xi-Yan, Zhu Yu-Tian, Ye Yang, Li Dong
机构信息
Department of Traditional Chinese Medicine, Peking University Third Hospital, Beijing 100191, China.
出版信息
World J Stem Cells. 2024 Sep 26;16(9):842-845. doi: 10.4252/wjsc.v16.i9.842.
Abstract
Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in liver cells and involves immune system activation, leading to histological changes, tissue damage, and clinical symptoms. A recent publication by Jiang , highlighted the potential of MSCs to mitigate in NAFLD progression by targeting various molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. In this editorial, we comment on their research and discuss the efficacy of MSC therapy in treating NAFLD.
摘要
间充质干细胞（MSCs）是干细胞治疗的常见来源，在调节先天性和适应性免疫反应中发挥关键作用。非酒精性脂肪性肝病（NAFLD）的特征是肝细胞中甘油三酯的积累，并涉及免疫系统激活，导致组织学变化、组织损伤和临床症状。蒋等人最近发表的一篇文章强调了间充质干细胞通过靶向各种分子途径（包括糖脂代谢、炎症、氧化应激、内质网应激和纤维化）来减轻NAFLD进展的潜力。在这篇社论中，我们对他们的研究进行评论，并讨论间充质干细胞疗法在治疗NAFLD中的疗效。
相似文献
1
Mechanism of mesenchymal stem cells in liver regeneration: Insights and future directions.间充质干细胞在肝脏再生中的机制：见解与未来方向。
World J Stem Cells. 2024 Sep 26;16(9):842-845. doi: 10.4252/wjsc.v16.i9.842.
2
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease.间充质干细胞作为非酒精性脂肪性肝病潜在治疗策略的当前观点。
World J Stem Cells. 2024 Jul 26;16(7):760-772. doi: 10.4252/wjsc.v16.i7.760.
3
Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease.间充质干细胞：非酒精性脂肪性肝病的一条有前景的治疗途径。
World J Stem Cells. 2024 Aug 26;16(8):780-783. doi: 10.4252/wjsc.v16.i8.780.
4
Innovative mesenchymal stem cell treatments for fatty liver disease.用于治疗脂肪肝疾病的创新性间充质干细胞疗法。
World J Stem Cells. 2024 Sep 26;16(9):846-853. doi: 10.4252/wjsc.v16.i9.846.
5
The role of the immune system in the pathogenesis of NAFLD and potential therapeutic impacts of mesenchymal stem cell-derived extracellular vesicles.免疫系统在 NAFLD 发病机制中的作用及间充质干细胞衍生的细胞外囊泡的潜在治疗作用。
Stem Cell Res Ther. 2022 Jun 7;13(1):242. doi: 10.1186/s13287-022-02929-6.
6
Liraglutide in combination with human umbilical cord mesenchymal stem cell could improve liver lesions by modulating TLR4/NF-kB inflammatory pathway and oxidative stress in T2DM/NAFLD rats.利拉鲁肽联合人脐带间充质干细胞通过调节 TLR4/NF-κB 炎症通路和氧化应激改善 2 型糖尿病/非酒精性脂肪性肝病大鼠的肝损伤。
Tissue Cell. 2020 Oct;66:101382. doi: 10.1016/j.tice.2020.101382. Epub 2020 May 12.
7
Innovative preconditioning strategies for improving the therapeutic efficacy of extracellular vesicles derived from mesenchymal stem cells in gastrointestinal diseases.创新预处理策略提高间充质干细胞来源细胞外囊泡在胃肠道疾病中的治疗效果。
Inflammopharmacology. 2023 Dec;31(6):2973-2993. doi: 10.1007/s10787-023-01350-6. Epub 2023 Oct 24.
8
Human umbilical cord-derived mesenchymal stem cell-exosomal miR-627-5p ameliorates non-alcoholic fatty liver disease by repressing FTO expression.人脐带间充质干细胞来源的细胞外囊泡 miR-627-5p 通过抑制 FTO 表达改善非酒精性脂肪性肝病。
Hum Cell. 2021 Nov;34(6):1697-1708. doi: 10.1007/s13577-021-00593-1. Epub 2021 Aug 19.
9
Endoplasmic reticulum stress in innate immune cells - a significant contribution to non-alcoholic fatty liver disease.内质网应激在固有免疫细胞中的作用——对非酒精性脂肪性肝病的重要贡献。
Front Immunol. 2022 Jul 22;13:951406. doi: 10.3389/fimmu.2022.951406. eCollection 2022.
10
Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease.间质干细胞/基质细胞治疗酒精相关性肝病和非酒精性脂肪性肝病的最新进展。
Stem Cells Transl Med. 2024 Feb 14;13(2):107-115. doi: 10.1093/stcltm/szad082.
引用本文的文献
1
Global research trends in liver regeneration and immunomodulation: A perspective from bibliometric analysis.肝脏再生与免疫调节的全球研究趋势：文献计量学分析视角
Hum Vaccin Immunother. 2025 Dec;21(1):2524249. doi: 10.1080/21645515.2025.2524249. Epub 2025 Jul 1.
本文引用的文献
1
Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease.间充质干细胞作为非酒精性脂肪性肝病潜在治疗策略的当前观点。
World J Stem Cells. 2024 Jul 26;16(7):760-772. doi: 10.4252/wjsc.v16.i7.760.
2
The Crosstalk between Mesenchymal Stromal/Stem Cells and Hepatocytes in Homeostasis and under Stress.间质基质/干细胞与肝细胞在稳态和应激中的串扰。
Int J Mol Sci. 2023 Oct 16;24(20):15212. doi: 10.3390/ijms242015212.
3
Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis.人脐带间充质干细胞来源的外泌体通过促进脂肪酸氧化和减少脂肪酸合成来改善肝脏脂肪变性。
JHEP Rep. 2023 Mar 28;5(7):100746. doi: 10.1016/j.jhepr.2023.100746. eCollection 2023 Jul.
4
Curcumin preconditioned mesenchymal stem cells derived exosomes transplantation ameliorate and protect against non- alcoholic steatohepatitis by regulation the expression of key genes of inflammation and oxidative stress.姜黄素预处理间充质干细胞来源的外泌体移植通过调节炎症和氧化应激关键基因的表达改善和保护非酒精性脂肪性肝炎。
Transpl Immunol. 2023 Jun;78:101837. doi: 10.1016/j.trim.2023.101837. Epub 2023 Apr 7.
5
Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells.肝脏再生中的干细胞疗法：聚焦间充质干细胞和诱导多能干细胞。
Pharmacol Ther. 2022 Apr;232:108004. doi: 10.1016/j.pharmthera.2021.108004. Epub 2021 Sep 28.
6
Feeder-free generation and transcriptome characterization of functional mesenchymal stromal cells from human pluripotent stem cells.从人多能干细胞中无饲养层生成功能性间充质基质细胞并进行转录组表征
Stem Cell Res. 2020 Oct;48:101990. doi: 10.1016/j.scr.2020.101990. Epub 2020 Sep 11.
7
IL-1 Pretreatment Improves the Efficacy of Mesenchymal Stem Cells on Acute Liver Failure by Enhancing CXCR4 Expression.白细胞介素-1预处理通过增强CXCR4表达提高间充质干细胞对急性肝衰竭的疗效。
Stem Cells Int. 2020 Jul 7;2020:1498315. doi: 10.1155/2020/1498315. eCollection 2020.
8
Liver Transplantation for Acute-on-Chronic Liver Failure: Science or Fiction?肝移植治疗慢加急性肝衰竭：是科学还是虚构？
Liver Transpl. 2020 Jul;26(7):906-915. doi: 10.1002/lt.25788.
9
Mesenchymal Stem Cell-Mediated Delivery of an Oncolytic Adenovirus Enhances Antitumor Efficacy in Hepatocellular Carcinoma.间质干细胞介导的溶瘤腺病毒递送增强肝癌的抗肿瘤疗效。
Cancer Res. 2019 Sep 1;79(17):4503-4514. doi: 10.1158/0008-5472.CAN-18-3900. Epub 2019 Jul 9.
10
Stem Cell-Based Therapies for Liver Diseases: An Overview and Update.基于干细胞的肝脏疾病治疗方法：概述与更新。
Tissue Eng Regen Med. 2019 Feb 21;16(2):107-118. doi: 10.1007/s13770-019-00178-y. eCollection 2019 Apr.
Zotero 插件